The study compares the efficacy and safety of the INBRX-106 combination therapy against pembrolizumab monotherapy in treatment-naïve patients expressing PD-L1 with a Combined Positive Score of at least 20. Designed to address the limitations of traditional bivalent antibodies, INBRX-106 uses a proprietary single-domain platform to achieve high-order receptor clustering, which the company claims is essential for robust T-cell activation and survival.
Inhibrx to Unveil HexAgon Phase 2 Results for HNSCC Treatment
San Diego-based Inhibrx Biosciences will host a live webcast on September 8, 2026, at 5:00 a.m. PT to disclose primary endpoint data from its HexAgon study. The trial evaluates INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab for patients with metastatic or unresectable head and neck squamous cell carcinoma.
Investors can access the presentation through the company’s investor relations portal or by dialing 1-888-880-3330 using conference ID 6981384. Following the live session, the data and updated corporate slides will remain available on the Inhibrx website for 60 days. This clinical milestone represents a key assessment of the company’s multivalent approach to protein engineering, which also includes the development of ozekibart.
Comments (0)
No comments yet. Be the first!